Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinkau, T.
Right arrow Articles by Mann, J. F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinkau, T.
Right arrow Articles by Mann, J. F. E.
J Am Soc Nephrol 15:517-523, 2004
© 2004 American Society of Nephrology


FRONTIERS IN NEPHROLOGY

How Does Minor Renal Dysfunction Influence Cardiovascular Risk and the Management of Cardiovascular Disease?

Tobias Pinkau*, Karl F. Hilgers{dagger}, Roland Veelken{dagger} and Johannes F. E. Mann{ddagger}

*Department of Cardiology, German Heart Center, Munich, Germany; {dagger}Department of Nephrology, University of Erlangen-Nuremberg, Erlangen, Germany; and {ddagger}Department of Nephrology and Hypertension, Schwabing General Hospital, Munich, Germany.

Correspondence to Dr. Johannes F. E. Mann, Professor of Medicine, Department of Nephrology and Hypertension, Schwabing General Hospital, Kolner Platz 1, Munchen 80804, Germany. Phone: 49893068-2386; Fax: 49893068-3917; E-mail: johannes.mann{at}kms.mhn.de

ABSTRACT. This review focuses on the association between mild renal insufficiency (stage 2 and 3 of chronic kidney disease) and cardiovascular disease and discusses therapeutic options. Although the association of chronic renal insufficiency and cardiovascular risk was first shown in patients with end-stage renal disease, even minor renal dysfunction is now established as an independent risk for atherosclerotic cardiovascular disease. The association has been established in patients with a high cardiovascular risk but also in the general population. Treatment with angiotensin-converting enzyme inhibitors and statins can reduce cardiovascular morbidity and mortality in patients with renal insufficiency. Coronary revascularization improves the prognosis in patients with minor renal dysfunction, but there is still an underutilization of coronary revascularization procedures in people with renal insufficiency. The use of coronary stenting has now reduced the incidence of restenosis in these patients, and there is hope that the development of new devices will improve the prognosis in patients with renal insufficiency as well. Nevertheless, people with cardiovascular disease and renal insufficiency die significantly more often than people without renal insufficiency independent of prior successful treatment. Further investigations should focus on the causes of and possible preventive interventions for the staggering cardiovascular risk in the ever-increasing number of people with minor renal dysfunction.




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the TNT (Treating to New Targets) Investigator
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1448 - 1454.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. F. E. Mann, P. Sheridan, M. J. McQueen, C. Held, J. M. O. Arnold, G. Fodor, S. Yusuf, E. M. Lonn, and on behalf of the HOPE-2 investigators
Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 645 - 653.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Chonchol, M. Cigolini, and G. Targher
Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 269 - 274.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Goncalves, R. Pecoits-Filho, S. Perreto, S. H. Barberato, A. E. M. Stinghen, E. G. A. Lima, R. Fuerbringer, S. M. Sauthier, and M. C. Riella
Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2788 - 2794.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Agarwal and M. J. Andersen
Correlates of Systolic Hypertension in Patients With Chronic Kidney Disease
Hypertension, September 1, 2005; 46(3): 514 - 520.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, and for the European Uremic Toxin Work Group (EUTox)
Chronic kidney disease as cause of cardiovascular morbidity and mortality
Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1048 - 1056.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP